Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 6,100 shares, a decrease of 57.9% from the March 31st total of 14,500 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 14,800 shares, the short-interest ratio is presently 0.4 days.

Artelo Biosciences Stock Performance

ARTL stock remained flat at $1.34 on Friday. The company had a trading volume of 5,726 shares, compared to its average volume of 8,131. The stock’s 50-day simple moving average is $1.49 and its 200 day simple moving average is $1.43. Artelo Biosciences has a 1 year low of $1.15 and a 1 year high of $2.98. The firm has a market capitalization of $4.33 million, a PE ratio of -0.43 and a beta of 1.45.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings results on Monday, March 25th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.70). As a group, sell-side analysts forecast that Artelo Biosciences will post -2.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Artelo Biosciences in a report on Tuesday, April 2nd.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD.